Evidence map›Paper›PMID 34100767›Full record

ArticleJMIR mHealth and uHealth2021

The SleepFit Tablet Application for Home-Based Clinical Data Collection in Parkinson Disease: User-Centric Development and Usability Study.

Alessandro Mascheroni, Eun Kyoung Choe, Yuhan Luo, Michele Marazza, Clara Ferlito, Serena Caverzasio, Francesco Mezzanotte, Alain Kaelin-Lang, Francesca Faraci, Alessandro Puiatti and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02723396 (Sleep & Move. Systematic Characterisation of Sleep Benefit in Parkinson's Disease. An Observational, Prospective Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02723396 completednot on this map

Sleep & Move. Systematic Characterisation of Sleep Benefit in Parkinson's Disease. An Observational, Prospective Study

TypeobservationalSponsorNeurocenter of Southern SwitzerlandRan2016 to 2024Enrolled67ConditionsIdiopathic Parkinson Disease
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandro MascheroniInstitute of Information Systems and Networking, Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0003-4298-4784
Eun Kyoung Choe *College of Information Studies, University of Maryland, College Park, MD, United States.ORCID 0000-0001-5038-8320
Yuhan Luo *College of Information Studies, University of Maryland, College Park, MD, United States.ORCID 0000-0003-2016-4080
Michele Marazza *Information & Communication Technology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.ORCID 0000-0002-4348-8267
Clara Ferlito *Neurocenter of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-8166-7979
Serena Caverzasio *Neurocenter of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-3420-0313
Francesco MezzanotteNeurocenter of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0001-7421-9548
Alain Kaelin-LangNeurocenter of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-5249-073X
Francesca Faraci *Institute of Information Systems and Networking, Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-8720-1256
Alessandro Puiatti *Institute of Information Systems and Networking, Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-9745-1515
Pietro Luca Ratti *Neurocenter of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-9941-6721

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson disease (PD) is a common, multifaceted neurodegenerative disorder profoundly impacting patients' autonomy and quality of life. Assessment in real-life conditions of subjective symptoms and objective metrics of mobility and nonmotor symptoms such as sleep disturbance is strongly advocated. This information would critically guide the adaptation of antiparkinsonian medications and nonpharmacological interventions. Moreover, since the spread of the COVID-19 pandemic, health care practices are being reshaped toward a more home-based care. New technologies could play a pivotal role in this new approach to clinical care. Nevertheless, devices and information technology tools might be unhandy for PD patients, thus dramatically limiting their widespread employment.

objectiveThe goals of the research were development and usability evaluation of an application, SleepFit, for ecological momentary assessment of objective and subjective clinical metrics at PD patients' homes, and as a remote tool for researchers to monitor patients and integrate and manage data.

methodsAn iterative and user-centric strategy was employed for the development of SleepFit. The core structure of SleepFit consists of (1) an electronic finger-tapping test; (2) motor, sleepiness, and emotional subjective scales; and (3) a sleep diary. Applicable design, ergonomic, and navigation principles have been applied while tailoring the application to the specific patient population. Three progressively enhanced versions of the application (alpha, v1.0, v2.0) were tested by a total of 56 patients with PD who were asked to perform multiple home assessments 4 times per day for 2 weeks. Patient compliance was calculated as the proportion of completed tasks out of the total number of expected tasks. Satisfaction on the latest version (v2.0) was evaluated as potential willingness to use SleepFit again after the end of the study.

resultsFrom alpha to v1.0, SleepFit was improved in graphics, ergonomics, and navigation, with automated flows guiding the patients in performing tasks throughout the 24 hours, and real-time data collection and consultation were made possible thanks to a remote web portal. In v2.0, the kiosk-mode feature restricts the use of the tablet to the SleepFit application only, thus preventing users from accidentally exiting the application. A total of 52 (4 dropouts) patients were included in the analyses. Overall compliance (all versions) was 88.89% (5707/6420). SleepFit was progressively enhanced and compliance increased from 87.86% (2070/2356) to 89.92% (2899/3224; P=.04). Among the patients who used v2.0, 96% (25/26) declared they would use SleepFit again.

conclusionsSleepFit can be considered a state-of-the-art home-based system that increases compliance in PD patients, ensures high-quality data collection, and works as a handy tool for remote monitoring and data management in clinical research. Thanks to its user-friendliness and modular structure, it could be employed in other clinical studies with minimum adaptation efforts.

trial registrationClinicalTrials.gov NCT02723396; https://clinicaltrials.gov/ct2/show/NCT02723396.

Indexed as

COVID-19Parkinson DiseaseData CollectionHumansPandemicsQuality of LifeSARS-CoV-2ecological momentary assessmentfinger-tapping testhome-based systemParkinson diseasesleep diariessubjective scalestablet application

Identifiers

PMID34100767
PMCPMC8262669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.